Colon carcinoma, liver metastases
Conditions
Interventions
None listed
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with primary colorectal cancerCachectic patient group (n=18)Age = 18Stage I, II, or III colorectal cancerPlanned segmental colectomy for primary colorectal cancerCRP = 5mg/L, SAT Z-score <0, SM-RA Z-score <0Non-cachectic patient group (n=18)Age = 18Stage I, II or III colorectal cancerPlanned segmental colectomy for primary colorectal cancerCRP < 5mg/L, SAT Z-score <0, SM-RA Z-score =0 Patients with colorectal liver metastasesCachectic patient group (n=18)Age = 18Planned liver resection for colorectal liver metastasisCRP = 5mg/L, SAT Z-score <0, SM-RA Z-score <0Non-cachectic patient group (n=18)Age = 18Planned liver resection for colorectal liver metastasisCRP < 5mg/L, SAT Z-score <0, SM-RA Z-score =0
Exclusion criteria
Exclusion criteria: Body composition metrics outside of the ranges mentioned in the inclusion criteriaKnown history of diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| he primary outcome parameters of this study is whole-body insulin stimulated glucose uptake expressed per kg body weight and per unit of plasma insulin concentration (M/I-value (mg/kg/min per pmol/L)) as well as homeostatic model assessment for Insulin resistance (HOMA-IR). | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome parameters are 1) insulin-stimulated glucose uptake (Ki) in skeletal muscle, adipose tissue, liver, and tumour measured by [18F]-FDG PET, and 2) Plasma and tissue inflammatory cytokine levels measured with ELISA or qPCR. | — |
Countries
Netherlands
Contacts
Public ContactDPJ Dijk
Universiteit Maastricht
Outcome results
None listed